Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)

Starting soon · Not applicable

Conditions studied: Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

In brief

The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and inadequately controlled Type 2 Diabetes (T2D) despite guideline-directed therapy, including Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)-based agents.

Key facts

Study ID

NCT07639684

Run by

Boston Scientific Corporation

People needed

50

Starts

2027-02-01

Expected to finish

2029-05-01

Last updated by the study team

2026-07-24

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to provide written informed consent to participate in the study
• Age ≥ 22 years
• BMI 30 - 50 kg/m2
• HbA1c 7.5 - 10.5%
• Type 2 Diabetes treated with incretin-based medication (aka GLP-1RA agonist or GLP-1RA/GIP dual agonist) at a stable, maximal tolerated dose for a minimum of 6 months +/- any other oral glucose lowering medications AND intention to initiate insulin therapy for glycemic management
• Stable weight (< 5% TBW) within the 3 months prior to screening
• Meets the indications for ESG procedure with OverStitch™ or OverStitch NXT™ Endoscopic Suturing System, excluding the following but not limited to the following: large hiatal hernia, potential bleeding gastric lesions (e.g. ulcers; erosive gastritis; varices; or vascular malformation), coagulopathy and antiplatelet/anticoagulant therapy that cannot be corrected
• Declines or is ineligible for metabolic bariatric surgery
• Agrees to abstain from taking any weight loss treatments or supplements that are not part of the lifestyle modification program for a year following the ESG procedure
• Willing and able to comply with the study procedure with standard of care lifestyle modification program and visit schedule.

You may not qualify if…

• Diabetes management with insulin. Prior use of insulin for gestational diabetes or short-term use (up to 1 month) in conjunction with an acute condition is acceptable.
• Noncompliance with medication regime for diabetic management
• More than one episode of clinically significant reactive or severe hypoglycemia within the prior 1 year. Reactive hypoglycemia is defined as postprandial hypoglycemia meeting Whipple's Triad; severe hypoglycemia is defined as any hypoglycemic episode requiring assistance from another person to administer carbohydrates, glucagon, or other corrective/resuscitative action
• History of ketoacidosis or hyperosmolar nonketotic coma within the past 1 year
• Has a contraindication for ESG procedure with OverStitch™ or OverStitch NXT™ Endoscopic Suturing System, including but not limited to the following: large hiatal hernia, potential bleeding gastric lesions (e.g. ulcers; erosive gastritis, varices, or vascular malformation), coagulopathy and antiplatelet/anticoagulant therapy that cannot be correct
• Prior gastric surgery, including but not limited to LSG or RYGP
• Any known conditions that impact weight loss or glycemic management
• Chronic systemic steroids or immunosuppressants taken at the time of enrollment or likely required during the study follow-up
• CKD stage 3+, defined as eGFR < 60 mL/min
• Persistent anemia, defined as hemoglobin < 10 g/dL
• Excessive alcohol consumption, defined as meeting or exceeding sex-based heavy drinking limits
• Use within the last three months prior to screening of over the counter or prescribed weight loss supplements / medications, or intent to use any weight loss medications or supplements during the study duration.
• The investigator's medical judgment that the subject is not a candidate for the ESG procedure due to findings, including but not limited to psychological and nutritional evaluation results obtained in the prior 12 months.
• Current pregnancy confirmed by site standard of care or planned pregnancy or breastfeeding for a year following the ESG procedure.
• Vulnerable subject.
• Current or planned participation in another clinical study.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.